• Denali Therapeutics Inc DNLI.OQ reported a quarterly adjusted loss of 67 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from $-1.13 to -34 cents per share.

• Reported revenue was zero​; analysts expected $10.70 million.

• Denali Therapeutics Inc's reported EPS for the quarter was a loss of 67 cents​.

• The company reported a quarterly loss of $114.75 million.

• Denali Therapeutics Inc shares had fallen by 7.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Denali Therapeutics Inc is $37.50

This summary was machine generated from LSEG data February 27 at 09:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)